Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for

Jochen Mundschenk1, Nicole Unger, Stefan Schulz

  • 1Department of Endocrinology and Metabolism, Otto-von-Guericke-University, D-39120 Magdeburg, Germany.

Insights

Octreotide scintigraphy for pheochromocytoma relies on specific somatostatin receptor subtypes. Membrane-associated somatostatin receptor subtype 3 (sst3) can facilitate imaging when sst2A is absent.

Area of Science:

  • Endocrinology
  • Oncology
  • Nuclear Medicine

Background:

  • Octreotide, a somatostatin analog, is used for imaging and treating human tumors.
  • Data on somatostatin receptor subtypes in pheochromocytoma are limited.
  • Pheochromocytomas can express multiple somatostatin receptors, complicating octreotide's functional mechanism.

Purpose of the Study:

  • To investigate somatostatin receptor protein expression in pheochromocytoma.
  • To determine the role of specific somatostatin receptor subtypes in octreotide scintigraphy.
  • To explore potential therapeutic targets for pheochromocytoma.

Main Methods:

  • Immunohistochemical staining of 52 pheochromocytomas using anti-sst(1-5) and anti-SS-14 antibodies.
  • Analysis of staining pattern, distribution, and subcellular localization of somatostatin receptor subtypes.
  • (111)In-octreotide scintigraphy in 17 patients.

Main Results:

  • 90% of tumors showed positive immunohistochemical staining for sst(3).
  • Immunoreactive sst(2A) receptors were found in only 25% of tumors.
  • Scintigraphy was successful with sst(2A) presence; in its absence, membrane-associated sst(3) enabled true-positive results.

Conclusions:

  • Selective expression of membrane-associated sst(3) is sufficient for octreotide scintigraphy in some pheochromocytomas.
  • Pheochromocytomas with functional sst(3) may be targets for novel somatostatin receptor agonists.
  • Understanding receptor subtypes is crucial for optimizing octreotide-based diagnostics and therapeutics.